Co-Diagnostics, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
CODX$0.29-9.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Years Ended December 31, | ||||
|---|---|---|---|---|
| 2025 · 2024 | ||||
| Cash flows from operating activities | ||||
| Net loss | $(46,895,936) | $(37,639,008) | ||
| Adjustments to reconcile net loss to cash used in operating activities: | ||||
| Depreciation and amortization | 1,106,808 | 1,377,266 | ||
| Impairment charges | 18,882,000 | - | ||
| Stock-based compensation expense | 2,248,053 | 5,434,904 | ||
| Common stock issued for financial advisory services | 135,000 | - | ||
| Change in fair value of acquisition contingencies | (805,863) | (714,876) | ||
| Non-cash lease expense | (8,197) | 13,510 | ||
| Realized gain on investments | (683,365) | (870,745) | ||
| Loss from equity method investment | 46,301 | 186,067 | ||
| (Gain) loss on disposition of assets | 82,421 | (8,291) | ||
| Recoveries of credit losses | (26,006) | (15,035) | ||
| Inventory obsolescence expense (recovery) | (50,944) | 326,512 | ||
| Changes in assets and liabilities: | ||||
| Accounts receivable | (31,799) | 186,391 | ||
| Prepaid expenses and other assets | 585,926 | 412,056 | ||
| Inventory | 131,271 | 265,489 | ||
| Deferred revenue | (26,057) | (321,592) | ||
| Income taxes payable | (713,643) | 54,457 | ||
| Accounts payable, accrued expenses and other liabilities | (3,112,897) | 2,157,850 | ||
| Net cash used in operating activities | (29,136,927) | (29,155,045) | ||
| Cash flows from investing activities | ||||
| Purchases of property and equipment | (700,047) | (748,352) | ||
| Proceeds from maturities of marketable investment securities | 33,666,959 | 58,765,487 | ||
| Purchases of marketable securities | (6,590,939) | (40,802,588) | ||
| Investment in joint ventures | (102,566) | (143,750) | ||
| Net cash provided by investing activities | 26,273,407 | 17,070,797 | ||
| Cash flows from financing activities | ||||
| Proceeds from exercise of options | 12,500 | - | ||
| Issuance of common stock related to at-the-market offering, net of offering costs | 1,810,813 | 103,914 | ||
| Issuance of common stock related to registered direct offering, net of offering costs | 9,988,270 | - | ||
| Net cash provided by financing activities | 11,811,583 | 103,914 | ||
| Net increase (decrease) in cash and cash equivalents | 8,948,063 | (11,980,334) | ||
| Cash and cash equivalents at beginning of period | 2,936,544 | 14,916,878 | ||
| Cash and cash equivalents at end of period | $11,884,607 | $2,936,544 | ||
| Supplemental disclosure of cash flow information | ||||
| Cash received for income taxes | $(858,870) | $ | - | |
| Supplemental disclosure of non-cash investing and financing transactions | ||||
| Receivable from issuance of common stock, collected in 2025 | $ | - | $126,750 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.